David L. Tucker

Orthopedics

50 Dawn Ln
Airmont, NY 10901

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.

Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.

Journal: Blood advances

Published: February 04, 2026

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

Journal: Blood advances

Published: February 04, 2026

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Journal: Haematologica

Published: January 21, 2026

Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study.

Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study.

Journal: HemaSphere

Published: June 02, 2025

Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper.

Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper.

Journal: British journal of haematology

Published: May 06, 2025

Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL.

Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL.

Journal: Blood advances

Published: February 26, 2025

Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study.

Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: February 19, 2025

Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.

Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.

Journal: The Lancet. Infectious diseases

Published: October 01, 2024

Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.

Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.

Journal: Blood advances

Published: July 14, 2023

Termite sensitivity to temperature affects global wood decay rates.

Termite sensitivity to temperature affects global wood decay rates.

Journal: Science (New York, N.Y.)

Published: September 22, 2022

Quantification of cytosol and membrane proteins in rumen epithelium of sheep with low or high CH4 emission phenotype.

Quantification of cytosol and membrane proteins in rumen epithelium of sheep with low or high CH4 emission phenotype.

Journal: PloS one

Published: March 06, 2022

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.

Journal: Blood

Published: January 18, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026